In a report released today, Charles Rhyee from TD Cowen maintained a Buy rating on Walgreens Boots Alliance (WBA – Research Report), with a price target of $35.00. The company’s shares closed yesterday at $18.12.
According to TipRanks, Rhyee is a 4-star analyst with an average return of 3.5% and a 47.80% success rate. Rhyee covers the Healthcare sector, focusing on stocks such as Walgreens Boots Alliance, Teladoc, and Charles River Labs.
Currently, the analyst consensus on Walgreens Boots Alliance is a Hold with an average price target of $23.15.
Based on Walgreens Boots Alliance’s latest earnings release for the quarter ending February 29, the company reported a quarterly revenue of $37.05 billion and a GAAP net loss of $5.91 billion. In comparison, last year the company earned a revenue of $34.86 billion and had a net profit of $703 million
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of WBA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Walgreens Boots Alliance (WBA) Company Description:
Retail pharmacy leader Walgreens Boots Alliance (NASDAQ:WBA) operates through its namesake brand Walgreens in the U.S. and Boots in the U.K. In addition, it owns retail and business brands including the No7 Beauty Company, Duane Reade, Ahumada in Chile, and Benavides in Mexico. The company also targets equity investments in healthcare, pharmacy, and retail and has a presence in over 25 countries with more than 450,000 employees.
Read More on WBA:
